Hyperbaric Oxygenation (HBO) in Traumatic Spinal Cord Injury. (EOS) - Pilot Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03101982 |
Recruitment Status :
Recruiting
First Posted : April 5, 2017
Last Update Posted : March 16, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Hypothesis of the Study:
Based on the presented results, the investigator hypothesises that HBO preserves neurons that are not irreversibly damaged (i.e. severed) during initial trauma, thus enabling regain of their function. The investigator predicts that HBO treatment protects and enhances motor function in initially paralysed regions, including improvement in function of the extremities as well as recovery of urinary bladder control and bowel function.
Outline of the Proposed Study:
Within a prospective "proof of principle" trial, a total of 100 patients will be included. Fifty patients will be recruited at the Division of Thoracic and Hyperbaric Surgery, Medical University of Graz. In parallel, 50 control patients will be included at the Department of Orthopaedics and Trauma, Paracelsus University Salzburg, Salzburger Landeskliniken (SALK), Austria. Thereby, all patients that are admitted at the Medical University of Graz can be treated and the enrolment of 50 patients into the treatment group can be implemented within the outlined time frame. The active recruitment period is planned for three years. Both HBO treated and control patients will undergo the same surgical and nonsurgical procedures. HBO treatment will be started within 24 hours after the injury. A total of 21 consecutive daily sessions will be applied, followed by routine rehabilitation programmes. By matching control and HBO-treated patients, an evaluation of the treatment effect of HBO is possible. The outcome will be evaluated by implementing the American Spinal Injury Association (ASIA)-scores and magnet resonance (MR) imaging. Additionally, inflammatory and regenerative blood markers will be analysed (neuroendocrine markers/neuro-transmitters: S100beta, Brain Derived Neurotrophic Growth Factor [BDNF], Glial Fibrillary Acidic Protein [GFAP], Reactive Oxygen Species (ROS), norepinephrine; array of pro- and anti-inflammatory cytokines and chemokines).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Traumatic Injury of the Spinal Cord | Drug: HBO | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Hyperbaric Oxygenation (HBO) in Traumatic Spinal Cord Injury. (EOS) - Pilot Study |
Actual Study Start Date : | April 18, 2017 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | March 2025 |

Arm | Intervention/treatment |
---|---|
Active Comparator: test
HBO, ASIA score, blood taking
|
Drug: HBO
Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
Other Name: Hyperbaric oxygenation |
No Intervention: control
ASIA score, blood taking
|
- Improvement of neurological deficits caused by spinal cord lesions [ Time Frame: Change from baseline-admission scores ( ASIA ) at 12 months ]assessed by American Spinal Injury Association (ASIA) scores
- Correlation of clinical observations with blood parameters [ Time Frame: Blood samples will be taken at the time of admission, immediately before the first HBO, immediately after the first HBO, on days 1, 3, 7, 14 , 21 before the respective HBO, and at the 35 days and two months follow-up ]assessed by routinely taken blood tests

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 70 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Test cohort and control cohort:
- age: 16 to 70 years
- Traumatic spinal cord injury
- Initial incomplete or complete (ASIA) sensor/motoric dysfunction
- Mentally competent patient (no mental disability in history in case of intubated patient)
- No relevant neuromuscular diseases / neurological deficits before trauma
- Vertebral column stable, no relevant mechanical compression of spinal cord with our without surgical intervention within 24 hours after the injury;
- Spinal MRI and CT-scan within first 24 hours
Test cohort only:
- Cardiorespiratory situation allowing safe application of HBO
- Ability to equalize pressure differences in middle ear confirmed by an ENT (ear, nose, throat) physician or pretherapeutic myringotomy
- Circumstances allowing HBO-treatment to be started < 24 hours after the injury
Exclusion Criteria:
Test cohort and control cohort:
- Morphologically confirmed complete discontinuation of the spinal cord
- Cardio-respiratory instability
- Persistent seizure activity in spite of medication
- Craniocerebral injury exceeding mere commotion
- Pregnancy
- Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
- Simultaneous participation in another interventional study if relevant
Test cohort only:
- Cystic or bullous lung disease, untreated pneumothorax
- Treatment with doxorubicin in patient´s history

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03101982
Contact: Freyja Smolle-Jüttner | +43/316/ 385-13302 | freyja.smolle@medunigraz.at |
Austria | |
Medical University Graz | Recruiting |
Graz, Austria | |
Contact: Freyja Smolle-Jüttner +43/316/ 385-13302 freyja.smolle@medunigraz.at |
Responsible Party: | Medical University of Graz |
ClinicalTrials.gov Identifier: | NCT03101982 |
Other Study ID Numbers: |
HBOwings |
First Posted: | April 5, 2017 Key Record Dates |
Last Update Posted: | March 16, 2023 |
Last Verified: | March 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Spinal Cord Injuries Wounds and Injuries Spinal Cord Diseases |
Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System |